<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01131000</url>
  </required_header>
  <id_info>
    <org_study_id>CPI-CL-004</org_study_id>
    <nct_id>NCT01131000</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety, and Pharmacokinetics of Intravenous Ibuprofen in Adult Febrile Patients</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled Trial To Evaluate The Efficacy, Safety, and Pharmacokinetics of Ibuprofen Injection in Adult Febrile Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cumberland Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cumberland Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the efficacy of intravenous ibuprofen on&#xD;
      reducing fever at 4 hours.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to evaluate the efficacy of a single 400 mg dose of&#xD;
      intravenous ibuprofen on reducing fever greater than or equal to 101.0ºF (38.3ºC), as&#xD;
      compared with the efficacy of parallel placebo treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2002</start_date>
  <completion_date type="Actual">August 2005</completion_date>
  <primary_completion_date type="Actual">August 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of patients with fever reduction to less than 101.0 degree fahrenheit following a single dose of intravenous ibuprofen.</measure>
    <time_frame>4 hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">123</enrollment>
  <condition>Fever</condition>
  <arm_group>
    <arm_group_label>Ibuprofen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal Saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen</intervention_name>
    <description>Intravenous ibuprofen, 100 mg, Single-dose</description>
    <arm_group_label>Ibuprofen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen</intervention_name>
    <description>Intravenous ibuprofen, 200mg, single dose</description>
    <arm_group_label>Ibuprofen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen</intervention_name>
    <description>Intravenous ibuprofen, 400 mg, Single-dose</description>
    <arm_group_label>Ibuprofen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>Normal Saline, 100 ml, Single-dose</description>
    <arm_group_label>Saline</arm_group_label>
    <other_name>0.9 % NaCL; 0.9 % Sodium Chloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Be hospitalized&#xD;
&#xD;
          2. Have new (not chronic, within last 7 days) onset of fever, documented by temperature&#xD;
             greater than or equal to 101.0ºF (38.3ºC)&#xD;
&#xD;
          3. Have adequate intravenous access&#xD;
&#xD;
          4. Have the ability to understand the requirements of the study, be willing to provide&#xD;
             written informed consent (as evidenced by signature on an informed consent document&#xD;
             approved by an Institutional Review Board), and agree to abide by the study&#xD;
             restrictions and to return for the required assessments&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Be less than 18 years of age&#xD;
&#xD;
          2. Have received antipyretic drug therapy (e.g., aspirin, other NSAIDs, or acetaminophen)&#xD;
             within 4 hours before dosing&#xD;
&#xD;
          3. Have any history of allergy or hypersensitivity to any component of IVIb, NSAIDs&#xD;
             (including aspirin), or COX-2 inhibitors&#xD;
&#xD;
          4. Be pregnant or nursing&#xD;
&#xD;
          5. Have a history of severe head trauma that required current hospitalization,&#xD;
             intracranial surgery, or stroke within the previous 30 days, or any history of&#xD;
             intracerebral arteriovenous malformation, cerebral aneurysm, or central nervous system&#xD;
             mass lesions&#xD;
&#xD;
          6. Weigh less than 40 kg&#xD;
&#xD;
          7. Have a history of congenital bleeding diatheses (e.g., hemophilia) or any active&#xD;
             clinically significant bleeding, or have underlying platelet dysfunction, including&#xD;
             (but not limited to) idiopathic thrombocytopenic purpura, disseminated intravascular&#xD;
             coagulation, or congenital platelet dysfunction&#xD;
&#xD;
          8. Have gastrointestinal bleeding that has required medical intervention within the&#xD;
             previous 6 weeks (unless definitive surgery has been performed)&#xD;
&#xD;
          9. Have a platelet count less than 30,000/mm3&#xD;
&#xD;
         10. Be receiving full dose anticoagulation therapy&#xD;
&#xD;
         11. Have fever secondary to blood or drug reaction&#xD;
&#xD;
         12. Have an expected life span of less than 14 days because of imminent withdrawal of life&#xD;
             support or severity of illness&#xD;
&#xD;
         13. Be receiving treatment with corticosteroids (Patients who are expected to receive&#xD;
             corticosteroids during the Treatment Period or through Hour 120 of the Post-treatment&#xD;
             Period are not eligible.)&#xD;
&#xD;
         14. Have neurogenic fever&#xD;
&#xD;
         15. Be on dialysis, have oliguria or creatinine greater than 3.0 mg/dL, or be receiving&#xD;
             nephrotoxic drugs&#xD;
&#xD;
         16. Have had major surgery within the past 12 hours, unless adequate hemostasis has been&#xD;
             achieved&#xD;
&#xD;
         17. Have received another investigational drug within the past 30 days&#xD;
&#xD;
         18. Become afebrile (temperature below 101.0ºF [38.3ºC]) before dosing and not redevelop&#xD;
             fever entry criteria during this hospitalization&#xD;
&#xD;
         19. Be otherwise unsuitable for the study, in the opinion of the Investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gordon Bernard, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Cumberland Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Orlando Regional Medical Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barnes Jewish Hospital</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moses H. Cone Memorial Hospital</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Healthcare - University Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skyline Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ben Taub General Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newcastle Mater Misericordiae Hospital</name>
      <address>
        <city>New Lambton</city>
        <state>New South Wales</state>
        <zip>2305</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Flinders Medical Centre</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mahidol University Siriraj Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Thailand</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2010</verification_date>
  <study_first_submitted>May 24, 2010</study_first_submitted>
  <study_first_submitted_qc>May 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2010</study_first_posted>
  <last_update_submitted>May 25, 2010</last_update_submitted>
  <last_update_submitted_qc>May 25, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 26, 2010</last_update_posted>
  <responsible_party>
    <name_title>A. J. Kazimi, Chief Executive Office</name_title>
    <organization>Cumberland Pharmaceuticals Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperthermia</mesh_term>
    <mesh_term>Fever</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

